Granted Patent
B2
US 12,365,712 · App. 18/052,180 · Granted Jul 22, 2025
Single-chain TNF Receptor 2 agonist fusion proteins
Inventors:
David C. Foster (Euless, TX); Lutz B. Giebel (San Mateo, CA); Leonard G. Presta (San Francisco, CA)
Assignee:
Relinia, Inc.
C07K14/525A61P29/00A61K38/00A61K39/00C07K16/46C07K19/00C07K2319/02C07K2319/30C07K2319/50C07K2319/70C12N5/06C12N15/62
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This invention provides for a fusion protein between a single chain TNFR2 Selective Agonist protein (scTNFR2 Selective Agonist) and a dimerization domain, such as an IgGFc protein. The single chain TNFR2 Selective Agonist moiety provides a therapeutic activity by selectively activating the TNFR2 form of the TNF-α receptor, thus selectively stimulating Tregs and/or increasing myelin deposition.
Claims (7)
1. A nucleic acid encoding a fusion protein, wherein the nucleic acid comprises the sequence of SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38 or SEQ ID NO: 39.
2. An isolated host cell comprising the nucleic acid according to claim 1 .
3. The nucleic acid of claim 1 , wherein the fusion protein comprises SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 34 or SEQ ID NO: 35.
4. A pharmaceutical composition comprising the nucleic acid of claim 1 and a pharmaceutically acceptable carrier.
5. A nucleic acid encoding a fusion protein, wherein the fusion protein comprises the sequence selected from the group consisting of SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 118, SEQ ID NO: 119 and SEQ ID NO: 120.
6. A pharmaceutical composition comprising the nucleic acid of claim 5 and a pharmaceutically acceptable carrier.
7. An isolated host cell comprising the nucleic acid according to claim 5 .
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 12, 2025
From: FOSTER, DAVID C.; GIEBEL, LUTZ B.; PRESTA, LEONARD G.
To: RELINIA, INC.
Reel/Frame 071546/0418 →
Continuity (3)
Division
16618233
Provisional Application
62515643
· Jun 6, 2017
References Cited (113)
US 4179337A
· Davis et al.
· 1979
[cited by applicant]
US 4301144A
· Iwashita et al.
· 1981
[cited by applicant]
US 4496689A
· Mitra
· 1985
[cited by applicant]
US 4640835A
· Shimizu et al.
· 1987
[cited by applicant]
US 4670417A
· Iwasaki et al.
· 1987
[cited by applicant]
US 4791192A
· Nakagawa et al.
· 1988
[cited by applicant]
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 5648237A
· Carter
· 1997
[cited by applicant]
US 5739277A
· Presta et al.
· 1998
[cited by applicant]
US 5789199A
· Joly et al.
· 1998
[cited by applicant]
US 5840523A
· Simmons et al.
· 1998
[cited by applicant]
US 5959177A
· Hein et al.
· 1999
[cited by applicant]
US 6040498A
· Stomp et al.
· 2000
[cited by applicant]
US 6133426A
· Gonzalez et al.
· 2000
[cited by applicant]
US 6417429B1
· Hein et al.
· 2002
[cited by applicant]
US 6420548B1
· Vezina et al.
· 2002
[cited by applicant]
US 6946292B2
· Kanda et al.
· 2005
[cited by applicant]
US 7064191B2
· Shinkawa et al.
· 2006
[cited by applicant]
US 7125978B1
· Vezina et al.
· 2006
[cited by applicant]
US 7691568B2
· Niwa et al.
· 2010
[cited by applicant]
US 7700099B2
· Strohl
· 2010
[cited by applicant]
US 7749753B2
· Kanda et al.
· 2010
[cited by applicant]
US 8450460B2
· Hill et al.
· 2013
[cited by applicant]
US 9724390B2
· Gurney
· 2017
[cited by applicant]
US 20030157108A1
· Presta
· 2003
[cited by applicant]
US 20040093621A1
· Shitara et al.
· 2004
[cited by applicant]
US 20040110704A1
· Yamane et al.
· 2004
[cited by applicant]
US 20040132140A1
· Satoh et al.
· 2004
[cited by applicant]
US 20150056159A1
· Kontermann et al.
· 2015
[cited by applicant]
WO 199711971A1
· 1997
[cited by applicant]
WO 1999058572A1
· 1999
[cited by applicant]
WO 200442072A2
· 2004
[cited by applicant]
WO 2007106585A1
· 2007
[cited by applicant]
WO 2008079246A2
· 2008
[cited by applicant]
WO 2010010051A1
· 2010
[cited by applicant]
WO 2015148708A1
· 2015
[cited by applicant]
WO 2016070156A2
· 2016
[cited by applicant]
WO 2016156291A1
· 2016
[cited by applicant]
WO 2017040312A1
· 2017
[cited by applicant]
WO 201822675A1
· 2018
[cited by applicant]
WO 2018185247A1
· 2018
[cited by applicant]
WO 2020260368A1
· 2020
[cited by applicant]
WO 2023095913A1
· 2023
[cited by applicant]
WO 2024200987A1
· 2024
[cited by applicant]
WO 2024200988A1
· 2024
[cited by applicant]
WO 2024201144A1
· 2024
[cited by applicant]
WO 2024204896A1
· 2024
[cited by applicant]
Boschert et al. “Single chain TNF derivatives with individually mutated receptor binding sites reveal differential stoichiometry of ligand receptor complex formation for TNFR1 and TNER2,” Cellular Signaling 22 (2010) 10…
[cited by applicant]
Chopra et al. “Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion,” J. Exp. Med. Aug. 15, 2016, 2016, 1-20.
[cited by applicant]
Dong et al. “Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration,” PNAS, vol. 113, No. 43, Oct. 25, 2016, pp. 12304-12309.
[cited by applicant]
Faustman and Davis. “TNF receptor 2 and disease: autoimmunity and regenerative medicine,” Frontiers in Immunology, Dec. 2013, vol. 4, Article 478, pp. 1-8.
[cited by applicant]
Faustman and Davis. “TNF receptor 2 pathway: drug target for autoimmune diseases,” Nature Reviews, Jun. 2010, vol. 9, pp. 482-493.
[cited by applicant]
Fischer et al. “A TNF Receptor 2 Selective Agonist Rescues Human Neurons from Oxidative Stress-Induced Cell Death,” PLoS One Nov. 2011, vol. 6, Issue 11, pp. 1-11.
[cited by applicant]
Fischer et al. “Astrocyte-Specific Activation of TNFR2 Promotes Oligodendrocyte Maturation by Secretion of Leukemia Inhibitory Factor,” GLIA 2014; 62:272-283.
[cited by applicant]
Fischer et al. “Novel strategies to mimic transmembrane tumor necrosis factor-dependent activation of tumor necrosis factor receptor 2,” Scientific Reports, Jul. 26, 2017, 7:6607, 1-13.
[cited by applicant]
Fischer et al. “Selective Activation of Tumor Necrosis Factor Receptor II Induces Anti-inflammatory Responses and Alleviates Experimental Arthritis,” Arthritis & Rheumatology, vol. 70, No. 5, May 2018, 722-735.
[cited by applicant]
Fischer et al. “Targeting sTNF-TNFR1 Signaling as a New Therapeutic Strategy,” Antibodies 2015, 4, 48-70.
[cited by applicant]
Gao et al. “Opposing Functions of Microglial and Macrophagic TNFR2 in the Pathogenesis of Experimental Autoimmune Encephalomyelitis,” Cell Reports Jan. 3, 2017, 18, 198-212.
[cited by applicant]
He et al. “A TNFR2-Agonist Faciliatates High Purity Expansion of Low Purity Treg Cells,” PLoS One, May 25, 2016, vol. 11, Iss. 5, E01563311, pp. 1-17.
[cited by applicant]
Hutt et al. “Superior Properties of Fc-comprising scTRAIL Fusion Proteins,” Mol Cancer Ther; 16(12) Dec. 2017, 2792-2802.
[cited by applicant]
Krippner-Heidenreich et al. “Single-Chain TNF, a TNF Derivative with Enhanced Stability and Antitumoral Activity,” J Immunol 2008; 180:8176-8183.
[cited by applicant]
Liu et al. “Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: A comparative study with CHO prodcued materials.” Biologicals 39: 205-210 (2011).
[cited by applicant]
Loetscher et al. “Human Tumor Necrosis Factor a (TNF'a) Mutants with Exclusive Specificity for the 55-kDa or 75-kDTaN F' Receptors,” J. Bio. Chem., vol. 268, No. 36, Issue of Dec. 15, 1993, pp. 26360-26367.
[cited by applicant]
Madsen et al. “Oligodendroglial TNFR2 Mediates Membrane TNF Dependent Repair in Experimental Autoimmune Encephalomyelitis by Promoting Oligodendrocyte Differentiation and Remyelination,” Journal of Neuroscience, May 4, …
[cited by applicant]
Oganesyan Vaheh et al. “Structural characterization of a human Fc fragment engineered for lack of effector functions,” Acta Crystallographica Section D Biological Crystallography, vol. 64, No. 6, Jun. 1, 2008, pp. 700-7…
[cited by applicant]
Okubo et al. “Homogeneous Expansion of Human T-Regulatory Cells Via Tumor Necrosis Factor Receptor 2,” Scientific Reports, Nov. 2013, 3:3153, 1-11.
[cited by applicant]
Okubo et al. “Treg activation defect in type 1 diabetes: correction with TNFR2 agonism,” Clinical & Translational Immunology (2016) 5, e56, 1-9.
[cited by applicant]
Seifert et al. “The IgM CH2 Domain as Covalently Linked Homodimerization Module for the Generation of Fusion Proteins with Dual Specificity,” Protein Engineering, Design & Selection, Sep. 17, 2012, vol. 25, No. 10, pp. …
[cited by applicant]
Alegre, M L et al. “A non-activating “humanized” anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.” Transplantation vol. 57,11 (1994): 1537-43.
[cited by applicant]
Angal, S et al. “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody.” Molecular immunology vol. 30,1 (1993): 105-8.
[cited by applicant]
Armour, K L et al. “Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities.” European journal of immunology vol. 29,8 (1999): 2613-24.
[cited by applicant]
Armour, Kathryn L et al. “Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies.” Molecular immunology vol. 40,9 (2003): 585-93.
[cited by applicant]
Bolt, S et al. “The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.” European journal of immunology vol. 23,2 (1993): 403-11.
[cited by applicant]
Brenner, Dirk et al. “Regulation of tumour necrosis factor signalling: live or let die.” Nature reviews. Immunology vol. 15,6 (2015): 362-74.
[cited by applicant]
Challener, “Fusion Proteins Pose Manufacturability Challenges.” BioPharm International, May 1, 2017 30(5): 30-31, 37.
[cited by applicant]
Chen, Xiaoying et al. “Fusion protein linkers: property, design and functionality.” Advanced drug delivery reviews vol. 65,10 (2013): 1357-69.
[cited by applicant]
Chu, Seung Y et al. “Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies.” Molecular immunology vol. 45, 15 (2008): 3926-33.
[cited by applicant]
Cole, M S et al. “HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro.” Transplantation vol. 68,4 (1999): 563-71.
[cited by applicant]
Evans et al. “Design of Nonpeptidal Ligands for a Peptide Receptor: Cholecystokinin” (1987) J. Med. Chem., 30: 1229-1239.
[cited by applicant]
Gerngross, Tillman U. “Advances in the production of human therapeutic proteins in yeasts and filamentous fungi.” Nature biotechnology vol. 22,11 (2004): 1409-14.
[cited by applicant]
Graham, F L et al. “Characteristics of a human cell line transformed by DNA from human adenovirus type 5.” The Journal of general virology vol. 36,1 (1977): 59-74.
[cited by applicant]
Grell, M et al. “The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor.” Cell vol. 83,5 (1995): 793-802.
[cited by applicant]
Hutchins et al. “Improved biodistribution, tumor targetting, reduced immunogenicity in mice with a gamma4 variant of Campath-1H.” (1995) Proc Natl Acad Sci USA 92: 11980-11984.
[cited by applicant]
Kanda, Yutaka et al. “Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC.” Biotechnology and bioengineering vol. 94,4 (2006): 680-8.
[cited by applicant]
Lazar, Greg A et al. “Engineered antibody Fc variants with enhanced effector function.” Proceedings of the National Academy of Sciences of the United States of America vol. 103,11 (2006): 4005-10.
[cited by applicant]
Li, Huijuan et al. “Optimization of humanized IgGs in glycoengineered Pichia pastoris.” Nature biotechnology vol. 24,2 (2006): 210-5.
[cited by applicant]
Lightle, Sandra et al. “Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding.” Protein science : a publication of the Protein Society …
[cited by applicant]
Mather, J P et al. “Culture of testicular cells in hormone-supplemented serum-free medium.” Annals of the New York Academy of Sciences vol. 383 (1982): 44-68.
[cited by applicant]
Mather, J P. “Establishment and characterization of two distinct mouse testicular epithelial cell lines.” Biology of reproduction vol. 23,1 (1980): 243-52.
[cited by applicant]
McEarchern, Julie A et al. “Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities.” Blood vol. 109,3 (2007): 1185-92.
[cited by applicant]
Naismith, J H et al. “Crystallographic evidence for dimerization of unliganded tumor necrosis factor receptor.” The Journal of biological chemistry vol. 270,22 (1995): 13303-7.
[cited by applicant]
Okazaki, Akira et al. “Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIlla.” Journal of molecular biology vol. 336,5 (2004): 1239-49.
[cited by applicant]
Peters, Shirley J et al. “Engineering an improved lgG4 molecule with reduced disulfide bond heterogeneity and increased Fab domain thermal stability.” The Journal of biological chemistry vol. 287,29 (2012): 24525-33.
[cited by applicant]
Reddy, M P et al. “Elimination of Fc receptor-dependent effector functions of a modified lgG4 monoclonal antibody to human CD4.” Journal of immunology (Baltimore, Md. : 1950) vol. 164,4 (2000): 1925-33.
[cited by applicant]
Ripka et al. “Two Chinese Hamster Ovary Glycosylation Mutants Affected in the Conversion of GDP-Mannose to GDP-Fucose” (1986) Arch. Biochem. Biophys. 249: 533-545.
[cited by applicant]
Rizo and Gierasch “Constrained Peptides: Models of Bioactive Peptides and Protein SUBSTRUCTURES” (1992) Ann. Rev. Biochem. 61: 387-416.
[cited by applicant]
Sazinsky, Stephen L et al. “Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors.” Proceedings of the National Academy of Sciences of the United States of America vol. 105,51 (2008): 2016…
[cited by applicant]
Shields, R L et al. “High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.” The Journal of …
[cited by applicant]
U.S. Appl. No. 18/942,121, filed Nov. 8, 2024, Title: TNF-Alpha Variant Fusion Molecules.
[cited by applicant]
Urlaub, G, and L A Chasin. “Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity.” Proceedings of the National Academy of Sciences of the United States of America vol. 77,7 (1980): 421…
[cited by applicant]
White et al. “Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.” Cancer Cell Jan. 12, 2015;27(1):138-48.
[cited by applicant]
Xu, D et al. “In vitro characterization of five humanized OKT3 effector function variant antibodies.” Cellular immunology vol. 200,1 (2000): 16-26.
[cited by applicant]
Yamane-Ohnuki, Naoko et al. “Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity.”…
[cited by applicant]
Yazaki and Wu, Methods in Molecular Biology, vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, NJ), pp. 255-268 (2003).
[cited by applicant]